These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38167647)
1. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial. Cabrero M; López-Corral L; Jarque I; de la Cruz-Vicente F; Pérez-López E; Valcárcel D; Sanz J; Espigado I; Ortí G; Martín-Calvo C; de la Serna J; Caballero D; Bone Marrow Transplant; 2024 Mar; 59(3):359-365. PubMed ID: 38167647 [TBL] [Abstract][Full Text] [Related]
2. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Mei M; Palmer J; Tsai NN; Simpson J; O'Hearn J; Stein A; Forman S; Spielberger R; Cai JL; Htut M; Nakamura R; Al Malki MM; Herrera A; Wong J; Nademanee A Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e268-e276. PubMed ID: 37301631 [TBL] [Abstract][Full Text] [Related]
3. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979 [TBL] [Abstract][Full Text] [Related]
4. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860 [TBL] [Abstract][Full Text] [Related]
6. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176 [TBL] [Abstract][Full Text] [Related]
7. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Dodero A; Patriarca F; Milone G; Sarina B; Miceli R; Iori A; Barretta F; Terruzzi E; Mussetti A; Pini M; Bosi A; Dominietto A; Cascavilla N; Onida F; Narni F; Farina L; Rambaldi A; Corradini P Biol Blood Marrow Transplant; 2017 Jul; 23(7):1102-1109. PubMed ID: 28390983 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369 [TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745 [TBL] [Abstract][Full Text] [Related]
18. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI; Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879 [TBL] [Abstract][Full Text] [Related]
19. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Glass B; Hasenkamp J; Wulf G; Dreger P; Pfreundschuh M; Gramatzki M; Silling G; Wilhelm C; Zeis M; Görlitz A; Pfeiffer S; Hilgers R; Truemper L; Schmitz N; Lancet Oncol; 2014 Jun; 15(7):757-66. PubMed ID: 24827808 [TBL] [Abstract][Full Text] [Related]
20. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]